



Published in final edited form as:

*Pediatrics*. 2009 December ; 124(6): e1072–e1080. doi:10.1542/peds.2008-3074.

## Relative Impact of Influenza and Respiratory Syncytial Virus in Young Children

Florence T. Bourgeois, MD, MPH<sup>a,b</sup>, Clarissa Valim, MD, ScD<sup>c,d</sup>, Alexander J. McAdam, MD, PhD<sup>e</sup>, and Kenneth D. Mandl, MD, MPH<sup>a,b,f</sup>

<sup>a</sup>Division of Emergency Medicine, Children's Hospital Boston, Boston, Massachusetts

<sup>b</sup>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts

<sup>c</sup>Clinical Research Program, Children's Hospital Boston, Boston, Massachusetts

<sup>d</sup>Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts

<sup>e</sup>Department of Laboratory Medicine, Children's Hospital Boston, Boston, Massachusetts

<sup>f</sup>Children's Hospital Informatics Program, Children's Hospital Boston, Boston, Massachusetts

### Abstract

**OBJECTIVE**—We measured the relative impact of influenza and respiratory syncytial virus (RSV) infections in young children in terms of emergency department (ED) visits, clinical care requirements, and overall resource use.

**METHODS**—Patients who were aged 7 years and treated in the ED of a tertiary care pediatric hospital for an acute respiratory infection were enrolled during 2 winter seasons between 2003 and 2005. We quantified health care resource use for children with influenza or RSV infections, and extrapolated results to estimate the national resource use associated with influenza and RSV infections.

**RESULTS**—Nationally, an estimated 10.2 ED visits per 1000 children were attributable to influenza and 21.5 visits per 1000 to RSV. Children who were aged 0 to 23 months and infected with RSV had the highest rate of ED visits with 64.4 visits per 1000 children. Significantly more children required hospitalization as a result of an RSV infection compared with influenza, with national hospitalization rates of 8.5 and 1.4 per 1000 children, respectively. The total number of workdays missed yearly by caregivers of children who required ED care was 246 965 days for influenza infections and 716 404 days for RSV infections.

**CONCLUSION**—For young children, RSV is associated with higher rates of ED visits, hospitalization, and caregiver resource use than is influenza. Our results provide data on the large number of children who receive outpatient care for influenza and RSV illnesses and serve to inform analyses of prevention programs and treatments for both influenza and RSV disease.

### Keywords

burden of illness; influenza; respiratory syncytial virus; emergency health services

---

Copyright © 2009 by the American Academy of Pediatrics

Address correspondence to Florence T. Bourgeois, MD, MPH, Children's Hospital Boston, Division of Emergency Medicine, 300 Longwood Ave, Boston, MA 02115. [florence.bourgeois@childrens.harvard.edu](mailto:florence.bourgeois@childrens.harvard.edu).

**FINANCIAL DISCLOSURE:** *The authors have indicated they have no financial relationships relevant to this article to disclose.*

Each year, influenza and respiratory syncytial virus (RSV) result in substantial morbidity among young children, with >40% of preschool-aged children experiencing an influenza illness and nearly 100% of children infected with RSV by 3 years of age.<sup>1–4</sup> Illnesses range from self-limited upper respiratory infections to life-threatening respiratory compromise and result in a high volume of yearly hospitalizations, outpatient visits, and antibiotic use.<sup>5–10</sup> These viruses exert considerable economic impact through medical expenses for affected children, missed workdays by parents, and the increased overall burden of disease across age groups, because children are the chief vectors of influenza transmission to the adult population.<sup>11–16</sup>

Effective strategies to reduce the burden of childhood respiratory illnesses require a better understanding of the relative impact of viral agents and the resources used for treating sick children. The disease burden associated with influenza and RSV has been estimated primarily through extrapolation from hospitalization rates<sup>6–8,17–19</sup>; however, a substantial portion of the resource use that is attributable to these viruses is in the outpatient setting.<sup>10,20–22</sup> Emergency department (ED) visits for influenza may be up to 30 times more common than hospitalizations,<sup>21</sup> making the ED a prime setting for measuring the societal burden of these viruses.

We hypothesized that RSV illness among young children results in greater health care and societal burden compared with influenza illness. Through the lens of ED use, we measured the relative impact of influenza and RSV infections in young children in terms of ED visits, clinical care requirements, and overall resource use.

## METHODS

### Study Design and Population

Data from 3 patient cohorts were used to estimate population-based rates of resource use associated with influenza and RSV infections among children who presented to EDs in Massachusetts and the United States (Fig 1). The resource-use cohort was used to quantify resource use for children with influenza and RSV infections. The cohort was collected as a convenience sample of patients who were prospectively enrolled in the ED of a tertiary care pediatric hospital in Massachusetts during 2 influenza and RSV seasons—December 2003 to April 2004 and November 2004 to May 2005—on the basis of local peak activity of these winter respiratory viruses.<sup>23,24</sup> Eligible patients were identified by research assistants and included children who were < 7 years of age and presented to the ED with an acute respiratory infection (ARI), defined as the presence of 2 or more of the following symptoms: fever, cough, sore throat, sneezing, congestion, or rhinorrhea. Patients who had neutropenia were excluded.<sup>25,26</sup> Viral testing was performed on all patients in this cohort to identify patients who had ARIs that resulted from influenza and RSV. The Children's Hospital Boston institutional review board approved the study.

Research assistants administered standardized interviews to parents of participants at the time of enrollment and again by telephone 7 to 10 days after the ED visit. Information was collected on the participant's illness, including previous health care visits, home medication administration, days of missed school, and parental lost workdays resulting from the child's illness. Specific medications were identified, including over-the-counter agents (eg, antipyretics, cold remedies) and antibiotics. Medical records for the ED visit and, when applicable, the hospitalization were reviewed by a physician. Data were extracted on medication, oxygen, and intravenous fluid administration; radiologic and laboratory testing; and discharge prescriptions, by using a standardized form.

The respiratory illness cohort was a retrospective cohort from the same pediatric hospital used to estimate the mean yearly incidence of ED visits for ARIs. This cohort included all visits by patients who were aged  $\geq 7$  years and presented to the ED with an ARI between December and April during a 5-year period from 2001 to 2006. These winter months represent the period with the greatest number of visits for viral ARIs.<sup>7,17</sup> Overall, 98% of laboratory-confirmed influenza specimens and 91% of RSV specimens were obtained during this period. ARIs were identified by using patient chief complaints, which are routinely recorded for all patient visits to the ED.<sup>27</sup> Data from this cohort were combined with data on the study ED's market share (ie, the proportion of visits to the study ED among all EDs in the state) to determine population-based rates of ED visits for ARIs.<sup>28</sup>

The viral test cohort was also retrospective and included all visits by patients who were aged  $\geq 7$  years and were evaluated in the ED with laboratory-confirmed influenza or RSV between December and April from 2001 through 2006. The laboratory tests were ordered by clinicians during routine clinical care. This cohort was used to calculate the mean yearly risks for influenza and RSV infections among patients with ARIs. The risks for influenza and RSV infections were based on the average of the yearly risks and weighted by the age distribution of children who presented to the study ED to correct for differences in the age distribution between children who were tested for influenza and RSV and children who presented to the ED. We previously demonstrated that these mean risks for viral infection are representative of the infection rates among children with known ARIs.<sup>29</sup> Five years of retrospective viral test results were used to obtain robust mean risks for influenza and RSV infections given the yearly fluctuation in viral activity.

Nasopharyngeal aspirates were obtained from patients in the resource-use cohort and tested for the presence of influenza virus A and B, RSV, parainfluenza virus types 1 through 3, adenovirus, enterovirus, and human metapneumovirus (during 2004–2005 season only). All specimens were tested for influenza virus with culture and reverse transcriptase–polymerase chain reaction (RT-PCR) and for RSV by direct immunofluorescent antibody stain (DFA) and RT-PCR.<sup>30,31</sup> A specimen was defined as influenza- or RSV-positive when either test was positive.<sup>7,21</sup> We tested for parainfluenza and adenovirus by culture only, for enterovirus by using culture and RT-PCR, and for rhinovirus and human metapneumovirus by using RT-PCR only. Children with viral co-infections were not included in the measurements of resource use to obtain accurate estimates of the use attributable to influenza and RSV specifically. Tests on patients in the viral test cohort included DFAs and viral culture for influenza A and B, RSV, parainfluenza virus types 1 through 3, adenovirus, and enterovirus. A specimen that tested positive for influenza A or B or for RSV by either DFA or culture was considered influenza- or RSV-positive, respectively.

### **Influenza- and RSV-Associated Resource-Use Rates**

Resources were grouped into clinical care requirements associated with the enrollment ED visit, resource use that occurred before and after the ED visit, and antibiotic use during the illness. The proportion of children who used each resource for influenza and RSV infections, as measured in the resource-use cohort, was multiplied by the rate of ED visits for influenza and RSV in Massachusetts and the United States.

### **Age-Specific Influenza- and RSV-Associated Resource-Use Rates**

National rates of ED visits specific to age groups (0–23 months, 2–4 years, and 5–7 years) were calculated following the same procedure as for the study population as a whole but using age-specific ARI incidences, proportions of influenza and RSV infections, and census data. The age-specific number of primary care visits and workdays lost by caregivers resulting from an ED-treated ARI were determined by multiplying the mean total number of

primary care visits and workdays missed by a caregiver per child by the mean yearly rate of ED visits for influenza and RSV infections per 1000 children in the United States.

### Statistical Analysis

We compared demographic and clinical characteristics of patients by using Pearson  $\chi^2$  and Fisher's exact tests, as appropriate. Details of the estimation of the yearly incidence of ARIs have been previously described.<sup>21</sup> All other rates and variances were estimated by using the  $\delta$  method and conditional probability rules.<sup>32</sup> To estimate the mean total number of primary care visits and workdays missed by a caregiver per child, we used overdispersed Poisson models.

All confidence intervals (CIs) were at the 95% level, and all test statistics were 2-sided with *P* values considered statistically significant at a .05  $\alpha$  level. Analyses were performed by using SAS 9.1 (Cary, NC) and S-plus 8.0 (Insightful, Seattle, WA).

## RESULTS

### Study Population

Among the resource-use cohort, 895 patients who presented to the ED with ARIs during the 2 consecutive influenza and RSV seasons were approached and eligible for participation. Of these, 708 (79%) were enrolled in the study. Among the 187 not enrolled, 42 were non-English-speaking and an interpreter was not available, and 145 refused to participate. A total of 67 (9.5%) enrolled patients were infected with influenza, 164 (23.2%) with RSV, and 144 (19%) with other viruses included in the testing protocol. Eight children with influenza infections had evidence of a viral co-infection (3 with RSV, 2 with parainfluenza virus, and 3 with rhinovirus), and 13 children with RSV infections were infected with a second virus (3 with influenza, 2 with parainfluenza virus, and 8 with rhinovirus).

### Demographic and Clinical Characteristics

Patients who were infected with influenza and RSV were similar in terms of gender and race/ethnicity distribution, but age distributions differed (Table 1). There were also differences in terms of the living environment, medical history, clinical presentation, and diagnoses given to patients with influenza and RSV infections.

### Local and Population-Based Influenza and RSV ED Visit Rates

The mean yearly number of visits for ARIs to the study ED was 5288 (95% CI: 4770–5806), with 11.2% (95% CI: 0.6–21.8) infected with influenza and 23.6% (95% CI: 13.8–33.5%) infected with RSV. The ED visit rate for ARIs per 1000 children in Massachusetts was 76.6 (95% CI: 69.2–84.8) and nationally was 91.2 per 1000 children.

A total of 8.6 (95% CI: 3.3–22.4) per 1000 children in Massachusetts required an ED visit for an influenza infection and 18.1 (95% CI: 11.7–28.0) per 1000 required a visit for an RSV infection. At the national level, there were an estimated 10.2 visits (95% CI: 4.0–26.4) per 1000 children related to influenza and 21.5 visits (95% CI: 14.2–32.7) per 1000 to RSV.

### Influenza- and RSV-Associated Resource-Use Rates

There were differences in the clinical care requirements for children who were infected with influenza and RSV (Table 2). Compared with children who were infected with influenza, children with RSV were significantly more likely to have medications administered (74% [95% CI: 68%–81%] vs 49% [95% CI: 38%–64%], respectively; *P* < .001 for Pearson  $\chi^2$ ) with the difference primarily attributable to greater rates of over-the-counter medication

administration at home. Children with RSV were also more likely to have a radiologic study (69% [95% CI: 62%–77%] vs 44% [95% CI: 33%–59%], respectively;  $P < .001$  for Pearson  $\chi^2$ ) in the ED and were more likely to be admitted to the hospital (40% [95% CI: 33%–48%] vs 14% [95% CI: 7%–26%], respectively;  $P = .02$  for Pearson  $\chi^2$ ; Table 2). National estimates for the rate of hospitalization for RSV infection were significantly higher than for influenza.

Measures of overall resource use were high both for children with influenza and RSV infections (Table 3). Approximately 90% of children required some type of additional health care encounter. Almost two thirds of caregivers missed at least 1 day of work as a result of the child's illness. The estimated total number of workdays missed per year on a national basis by caregivers of children with influenza and RSV infections was 246 965 days and 716 404 days, respectively. Antibiotics were frequently administered to children with influenza and RSV infections, with 45% of children with influenza and 53% of children with RSV receiving antibiotics at some point during the course of their illness (Table 4).

### Age-Specific Influenza- and RSV-Associated Resource-Use Rates

ED visit rates were highest among children who were aged 0 to 4 years, with higher rates attributable to RSV infections compared with influenza. Children who were younger than 2 years and infected with RSV had 64.4 (95% CI: 45.4–91.3) ED visits per 1000 children who were younger than 2 years compared with 15.0 (95% CI: 4.4–50.6) visits per 1000 children among those who were infected with influenza (Fig 2). National rates of workdays missed by a caregiver, visits to primary care physicians, and prescription of an antibiotic to children were highest among children who were aged 0 to 4 years and had an RSV-associated infection and were similar in magnitude among children who were aged 5 to 7 years and had either an RSV or influenza illness (Fig 3).

## DISCUSSION

Our findings indicate that RSV causes a substantially greater burden in young children and their families than influenza. ARIs caused by RSV result in more than twice as many ED visits and 6 times as many hospitalizations compared with ARIs related to influenza. RSV infections are also twice as likely to result in additional primary care clinic visits and in antibiotic treatment. The parents of children with RSV miss almost 3 times more workdays than parents of children with influenza, and those with children younger than 2 years are nearly 5 times more likely to miss work when their child has RSV. Because the economic burden of childhood illnesses is largely driven by lost caregiver wages,<sup>33–35</sup> prevention and control approaches that address RSV as well as influenza among young children are likely to be most cost-effective.

Detailed guidelines that summarize recommendations for the containment of influenza infection are published every year by the Influenza Division of the Centers for Disease Control and Prevention.<sup>36,37</sup> These include well-developed influenza vaccination policies, guidelines for the use of antiviral medications, and control measures for specific settings such as child care facilities and nursing homes. Similar strategies are not available for the containment of RSV. Despite many years of vaccine research, prevention measures for RSV remain limited to immunoprophylaxis of children at high risk.<sup>38,39</sup> A better understanding of the contribution of RSV to the yearly burden of winter respiratory infections will serve to inform the development of prevention initiatives and to identify at-risk populations and cost-effective policies.

Although we provide new data on resource use in the clinical and outpatient settings, the rates of viral infection are consistent with previous studies, lending external validation to our

methods. Similar to our laboratory-confirmed positivity rates of 11.2% for influenza and 23.6% for RSV infections among children who were aged 7 years and had ARIs, published estimates of viral prevalence among children range from 6% to 16% for influenza<sup>21,40–43</sup> and 20% to 48% for RSV<sup>40–42</sup> during seasons and among patient populations that are different from the ones studied here. Poehling et al<sup>21</sup> reported ED visit rates for influenza of 6 and 27 per 1000 children aged 0 to 4 years during 2 influenza seasons, comparable to the rate in this study of 10.2 per 1000 children. In a recent study by Hall et al,<sup>25</sup> ED visit rates for RSV illnesses were found to range from 22 to 32 for children aged 0 to 4 years, similar to the rate of 21.5 per 1000 children reported in this study. Hospitalization rates reported in the literature are also similar to ours, ranging from 0.6 to 1.8 per 1000 children<sup>5,7,8,17,18,20,42,43</sup> for influenza infections and 3.0 to 5.8 per 1000 children for RSV illnesses<sup>6–8,18,25,42,44</sup> among children in similar age groups.

Additional support for the accuracy of our findings is the similarity in the rates that we report for the state and national populations. We calculated estimates for the Massachusetts population by using public health data, which include counts of all visits to Massachusetts EDs.<sup>28</sup> To obtain national estimates, we used a survey conducted by the National Center for Health Statistics, which collects information on national samples of visits to US EDs and allows computation of national estimates on the basis of proportional weights assigned to surveyed visits.<sup>45</sup> These 2 approaches yielded very similar results with slightly higher estimates for the national rates but none appreciably different from the state-level figures.

The methods used in this study—using cohort data in combination with public health and national survey data—may serve as a model for estimating the disease burden of other infectious and noninfectious illnesses. A similar approach has been used in studies published by the New Vaccine Surveillance Network, which conducts population-based surveillance of ARIs among children who are younger than 5 years.<sup>21,25</sup> In those studies, surveillance is conducted in 3 counties in the United States, and population estimates of virus-specific infections are obtained by using local market share rates, US Census figures, and National Hospital and Ambulatory Medical Care Survey data.

Our study has several limitations. In the resource-use cohort, our enrollment rate was high, but it is possible that a nonparticipation bias affected our resource-use rates. It is also possible that there were inaccuracies in the information provided by parents, which we were not able to verify; however, it is unlikely that there was a systematic bias toward either RSV or influenza infection. Our results are based on a patient population from a single institution, possibly limiting the generalizability of our findings. We assumed that results of virologic testing from our sample were applicable to all patients who were treated in the ED with ARIs. This assumption is supported by comparable rates found in our prospective cohort and from published reports.<sup>21,40–43</sup> To extrapolate to the state-level population, we assumed that the other state EDs had similar rates of visits for ARIs as well as influenza and RSV infections. For national estimates, we assumed that the rate of influenza and RSV infections was the same among ARI visits as in our study population. The use of National Hospital and Ambulatory Medical Care Survey data and this method, however, is consistent with the approach used in a previous study that examined national rates of ED visits for influenza.<sup>21</sup> Finally, we may have underestimated the total burden of influenza and RSV by excluding visits with viral co-infections, although there were similar rates of co-infections among patients with influenza and RSV. None of these limitations should impede our main objective to make relative comparisons between influenza- and RSV-associated health care use. In fact, the total burden of RSV may have been underestimated in this study, because the RSV season may begin as early as November and we chose to include only December through April in our definition of the winter season; however, a recent article reported the medical onset of yearly RSV outbreaks as December 1.<sup>25</sup>

## CONCLUSIONS

RSV has a substantially greater impact on young children than influenza, and because young children drive transmission of viral infections to older age groups,<sup>11,12</sup> they likely contribute to a large burden across the age spectrum. Infection control measures should take into account the relative impact of these viruses and provide strategies for RSV as well as influenza prevention. Our results highlight the impact of these viruses on the health care system and on caregivers and provide data necessary for cost/benefit analyses of prevention programs and treatments for influenza and RSV infection.

## Acknowledgments

This work was supported by R01LM007970 from the National Library of Medicine, 5 T32 HD40128 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, 5225 3 338CHI from the Massachusetts Department of Public Health, MO1 RR-02172 from the General Clinical Research Center at Children's Hospital Boston, and 290-00-0020 from the Agency for Healthcare Research and Quality.

We thank Jenny Wei, MD, Kelly Slack, MD, Jennifer Woo, MD, Hector Rivera, MD, and Sara Ivey, MPH, for assistance in data collection and processing; James West, PhD, for compilation of the registry data from the Massachusetts Division of Healthcare Finance and Policy; David Wypij, PhD, for suggestions on data analysis; Don Goldman, MD, for guidance and expertise in infectious diseases; and Karen Olson, PhD, for developing and managing the data sets.

## ABBREVIATIONS

<b>RSV</b>	respiratory syncytial virus
<b>ED</b>	emergency department
<b>ARI</b>	acute respiratory infection
<b>RT-PCR</b>	reverse transcriptase–polymerase chain reaction
<b>DFA</b>	direct immunofluorescent antibody stain
<b>CI</b>	confidence interval

## REFERENCES

1. Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved. *Epidemiol Infect.* 1993; 110(1):145–160. [PubMed: 8432318]
2. Simoes EA. Respiratory syncytial virus infection. *Lancet.* 1999; 354(9181):847–852. [PubMed: 10485741]
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. *JAMA.* 1999; 282(15):1440–1446. [PubMed: 10535434]
4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA.* 2003; 289(2):179–186. [PubMed: 12517228]
5. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. *N Engl J Med.* 2000; 342(4):225–231. [PubMed: 10648763]
6. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. *Pediatr Infect Dis J.* 2006; 25(9):795–800. [PubMed: 16940836]
7. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. *Pediatrics.* 2004; 113(6):1758–1764. [PubMed: 15173503]

8. Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. *Vaccine*. 2006; 24(1):102–108. [PubMed: 16310899]
9. Gaur AH, Hare ME, Shorr RI. Provider and practice characteristics associated with antibiotic use in children with presumed viral respiratory tract infections. *Pediatrics*. 2005; 115(3):635–641. [PubMed: 15741365]
10. Menec VH, Black C, MacWilliam L, Aoki FY. The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality. *Can J Public Health*. 2003; 94(1):59–63. [PubMed: 12583681]
11. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. *J Infect Dis*. 1970; 122(1):16–25. [PubMed: 5433709]
12. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. *Am J Epidemiol*. 1982; 115(5):736–751. [PubMed: 7081204]
13. Munoz FM. The impact of influenza in children. *Semin Pediatr Infect Dis*. 2002; 13(2):72–78. [PubMed: 12122955]
14. Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975–1979: II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. *Am J Epidemiol*. 1982; 116(2):228–242. [PubMed: 7114034]
15. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974–76. *N Engl J Med*. 1978; 298(11):587–592. [PubMed: 628375]
16. Brownstein JS, Kleinman KP, Mandl KD. Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system. *Am J Epidemiol*. 2005; 162(7):686–693. [PubMed: 16107568]
17. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *N Engl J Med*. 2000; 342(4):232–239. [PubMed: 10648764]
18. Weigl JA, Puppe W, Schmitt HJ. The incidence of influenza-associated hospitalizations in children in Germany. *Epidemiol Infect*. 2002; 129(3):525–533. [PubMed: 12558335]
19. Mangtani P, Hajat S, Kovats S, Wilkinson P, Armstrong B. The association of respiratory syncytial virus infection and influenza with emergency admissions for respiratory disease in London: an analysis of routine surveillance data. *Clin Infect Dis*. 2006; 42(5):640–646. [PubMed: 16447109]
20. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. *Pediatrics*. 2004; 113(3 pt 1):585–593. [PubMed: 14993554]
21. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. *N Engl J Med*. 2006; 355(1):31–40. [PubMed: 16822994]
22. Bourgeois FT, Valim C, Wei JC, McAdam AJ, Mandl KD. Influenza and other respiratory virus-related emergency department visits among young children. *Pediatrics*. 2006; 118(1) Available at: [www.pediatrics.org/cgi/content/full/118/1/e1](http://www.pediatrics.org/cgi/content/full/118/1/e1).
23. Centers for Disease Control and Prevention. [Accessed October 20, 2009] The National Respiratory and Enteric Virus Surveillance System (NREVSS). Available at: [www.cdc.gov/surveillance/nrevss/rsv/default.html](http://www.cdc.gov/surveillance/nrevss/rsv/default.html).
24. Centers for Disease Control and Prevention. [Accessed October 20, 2009] Flu activity & surveillance. Available at: [www.cdc.gov/flu/weekly/fluactivity.htm](http://www.cdc.gov/flu/weekly/fluactivity.htm).
25. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med*. 2009; 360(6):588–598. [PubMed: 19196675]
26. Miller EK, Griffin MR, Edwards KM, et al. Influenza burden for children with asthma. *Pediatrics*. 2008; 121(1):1–8. [PubMed: 18166550]
27. Beitel AJ, Olson KL, Reis BY, Mandl KD. Use of emergency department chief complaint and diagnostic codes for identifying respiratory illness in a pediatric population. *Pediatr Emerg Care*. 2004; 20(6):355–360. [PubMed: 15179142]




28. Massachusetts Division of Healthcare Finance and Policy. [Accessed October 20, 2009] Emergency department data. Available at: [www.mass.gov/?pageID=eohhs2terminal&L=5&L0=Home&L1=Researcher&L2=Physical+Health+and+Treatment&L3=Health+Care+Delivery+System&L4=DHCFP+Data+Resources&sid=Eeohhs2&b=terminalcontent&f=dhcfp\\_researcher\\_clinical\\_database&csid=Eeohhs2](http://www.mass.gov/?pageID=eohhs2terminal&L=5&L0=Home&L1=Researcher&L2=Physical+Health+and+Treatment&L3=Health+Care+Delivery+System&L4=DHCFP+Data+Resources&sid=Eeohhs2&b=terminalcontent&f=dhcfp_researcher_clinical_database&csid=Eeohhs2).
29. Bourgeois FT, Olson KL, Brownstein JS, Mc-Adam AJ, Mandl KD. Validation of syndromic surveillance for respiratory infections. *Ann Emerg Med*. 2006; 47(3):265.e1. [PubMed: 16492494]
30. Wright KE, Wilson GA, Novosad D, Dimock C, Tan D, Weber JM. Typing and subtyping of influenza viruses in clinical samples by PCR. *J Clin Microbiol*. 1995; 33(5):1180–1184. [PubMed: 7615726]
31. Mazzulli T, Peret TC, McGeer A, et al. Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward. *J Infect Dis*. 1999; 180(5):1686–1689. [PubMed: 10515833]
32. Fleiss, J.; Levin, B.; Park, M. *Statistical Methods for Rates and Proportions*. 3rd ed.. New York, NY: Wiley; 2003.
33. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. *Vaccine*. 2005; 23(8):1004–1014. [PubMed: 15620473]
34. Hardy AM, Lairson DR, Morrow AL. Costs associated with gastrointestinal-tract illness among children attending day-care centers in Houston, Texas. *Pediatrics*. 1994; 94(6 pt 2):1091–1093. [PubMed: 7971071]
35. Luce BR, Nichol KL, Belshe RB, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. *Vaccine*. 2008; 26(23):2841–2848. [PubMed: 18462851]
36. Centers for Disease Control and Prevention. [Accessed October 20, 2009] Seasonal influenza (flu). Available at: [www.cdc.gov/flu](http://www.cdc.gov/flu).
37. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. *MMWR Recomm Rep*. 2007; 56(RR-6):1–54. [PubMed: 17625497]
38. Power UF. Respiratory syncytial virus (RSV) vaccines: two steps back for one leap forward. *J Clin Virol*. 2008; 41(1):38–44. [PubMed: 18340669]
39. Stevens WW, Falsey AR, Braciale TJ. RSV 2007: recent advances in respiratory syncytial virus research. *Viral Immunol*. 2008; 21(2):133–140. [PubMed: 18570587]
40. Wolf DG, Greenberg D, Kalkstein D, et al. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. *Pediatr Infect Dis J*. 2006; 25(4):320–324. [PubMed: 16567983]
41. Jennings LC, Anderson TP, Werno AM, Beynon KA, Murdoch DR. Viral etiology of acute respiratory tract infections in children presenting to hospital: role of polymerase chain reaction and demonstration of multiple infections. *Pediatr Infect Dis J*. 2004; 23(11):1003–1007. [PubMed: 15545854]
42. Henrickson KJ, Hoover S, Kehl KS, Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. *Pediatr Infect Dis J*. 2004; 23(1 suppl):S11–S18. [PubMed: 14730265]
43. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. *Pediatrics*. 2006; 118(6):2409–2417. [PubMed: 17142526]
44. Fleming DM, Pannell RS, Elliot AJ, Cross KW. Respiratory illness associated with influenza and respiratory syncytial virus infection. *Arch Dis Child*. 2005; 90(7):741–746. [PubMed: 15855178]
45. National Center for Health Statistics. [Accessed October 20, 2009] Ambulatory health care data. Available at: [www.cdc.gov/nchs/ahcd.htm](http://www.cdc.gov/nchs/ahcd.htm).

**WHAT'S KNOWN ON THIS SUBJECT**


Winter respiratory viruses lead to substantial morbidity in young children. A better understanding of the relative impact of these viruses is required to inform the development of treatment and control measures.

**WHAT THIS STUDY ADDS**

Among young children, RSV results in a greater burden of illness than does influenza, with higher rates of ED visits and hospitalizations and greater caregiver resource utilization.


**FIGURE 1.**

Use of data sources in estimating state- and national-level rates of resource use for influenza and RSV infections that required ED care among children 8 years of age. NHAMCS indicates National Hospital and Ambulatory Medical Care Survey; MA, Massachusetts.



**FIGURE 2.**

Age-specific and mean national rates of ED visits for children with influenza and RSV infections. The mean rate of ED visits for influenza was 10.2 per 1000 children; the mean rate of ED visits for RSV was 21.5 per 1000 children.



**FIGURE 3.** National yearly rates of resource use for children with influenza and RSV infections. A, Workdays missed by caregiver. B, Visits to primary care clinics. C, Children prescribed an antibiotic.

TABLE 1

Demographic and Clinical Characteristics of Children Who Presented to the ED With Influenza and RSV Infections

Characteristic	Influenza (N = 59), % <sup>a</sup>	RSV (N = 151), % <sup>a</sup>	<i>pb</i>
Age			<.001
0–5 mo	15	37	
6–23 mo	12	22	
2–4 y	46	36	
5–7 y	27	5	
Female gender	49	44	.530
Race/ethnicity			.290
Non-Hispanic white	32	44	
Non-Hispanic black	20	17	
Hispanic	34	31	
Other	14	7	
Living environment			
Smoke exposure	15	26	.100
Child care attendance	31	31	.930
2 siblings	14	29	.020
>2 family members per bedroom	0	7	.060
Medical history			
Asthma <sup>c</sup>	36	38	.770
Other chronic illness	0	8	.020
Prematurity <sup>d</sup>	12	19	.200
Influenza immunized	27	31	.570
Clinical presentation			
Fever <sup>e</sup>	90	67	<.010
Cough	93	99	.010
Rhinorrhea	88	81	.200
Sore throat	24	10	<.010
Hypoxia <sup>f</sup>	14	38	<.010
Wheeze on auscultation	10	42	<.010
Crackles or rhonchi on auscultation	15	48	<.010
ED diagnosis <sup>g</sup>			
Otitis media	10	11	.820
Pneumonia	5	13	.090
Bronchiolitis	14	44	<.010
Asthma	5	16	.040
Influenza	5	0	.020
Febrile illness	25	5	<.010
Viral illness	25	20	.380

<sup>a</sup>Eight patients with influenza co-infections and 13 patients with RSV co-infections were excluded.

<sup>b</sup>*P* values were estimated by using Pearson's  $\chi^2$  except for the variables ">2 family members per bedroom," "other chronic illness," and "Influenza," for which Fisher's exact test was used.

<sup>c</sup>History of asthma or wheezing.

<sup>d</sup>Defined as <37 weeks' estimated gestational age.

<sup>e</sup>Defined as measured temperature at home or in ED of >37.9°C.

<sup>f</sup>Defined as oxygen saturation in ED of <97%.

<sup>g</sup>Includes primary and secondary diagnoses.

**TABLE 2**  
Clinical Care Requirements by Children 7 Years of Age With Influenza and RSV Infections

Treatment Administered or Intervention Performed	Influenza (N = 59)			RSV (N = 151)		
	Proportion (95% CI) Among Prospective Patients	Yearly Rate (95% CI) in Massachusetts Population/1000 Children	Yearly Rate (95% CI) in US Population/1000 Children	Proportion (95% CI) Among Prospective Patients	Yearly Rate (95% CI) in Massachusetts Population/1000 Children	Yearly Rate (95% CI) in US Population/1000 Children
Medication	49 (38–64)	4.2 (1.5–11.6)	5.0 (1.9–13.5)	74 (68–81)	13.4 (8.6–21.0)	16.0 (10.4–24.5)
Supplemental oxygen	2 (0–12)	0.1 (0.0–1.8)	0.2 (0.0–1.8)	14 (9–21)	2.5 (1.3–4.7)	3.0 (1.7–5.4)
Intravenous fluids	31 (21–45)	2.6 (0.9–7.6)	3.1 (1.1–8.8)	28 (22–37)	5.2 (3.1–8.7)	6.1 (3.7–10.0)
Radiologic study	44 (33–59)	3.8 (1.4–10.5)	4.5 (1.7–12.2)	69 (62–77)	12.5 (7.9–19.6)	14.8 (9.6–22.8)
Laboratory blood test	32 (22–47)	2.8 (1.0–8.0)	3.3 (1.2–9.2)	32 (26–41)	5.9 (3.5–9.8)	7.0 (4.3–11.3)
Urinalysis	20 (12–34)	1.7 (0.6–5.4)	2.1 (0.7–6.3)	13 (9–20)	2.4 (1.3–4.5)	2.8 (1.6–5.1)
Lumbar puncture	10 (5–22)	0.9 (0.2–3.3)	1.0 (0.3–3.7)	3 (1–8)	0.6 (0.2–1.7)	0.7 (0.3–1.9)
Hospital admission	14 (7–26)	1.2 (0.4–4.0)	1.4 (0.4–4.5)	40 (33–48)	7.2 (4.4–11.7)	8.5 (5.4–13.6)
Medication prescription	19 (11–32)	1.6 (0.5–5.1)	1.9 (0.6–5.8)	20 (14–27)	3.6 (2.0–6.3)	4.3 (2.5–7.3)



**TABLE 3**  
Resource Use by Children 7 Years of Age Treated in an ED for Influenza and RSV Infections

Type of Resource	Influenza (N = 58) <sup>a</sup>			RSV (N = 150) <sup>a</sup>		
	Proportion (95% CI) Among Prospective Patients	Yearly Rate (95% CI) in Massachusetts Population/1000 Children	Yearly Rate (95% CI) in US Population/1000 Children	Proportion (95% CI) Among Prospective Patients	Yearly Rate (95% CI) in Massachusetts Population/1000 Children	Yearly Rate (95% CI) in US Population/1000 Children
Any additional health care encounter <sup>b</sup>	90 (82–98)	7.7 (2.9–20.2)	9.2 (3.5–23.8)	93 (89–97)	16.9 (10.9–26.2)	20.1 (13.2–30.6)
Visit to primary care clinic	71 (60–83)	6.1 (2.3–16.2)	7.2 (2.7–19.0)	78 (72–85)	14.1 (9.0–22.1)	16.8 (10.9–25.7)
Additional visit to ED	21 (13–34)	1.8 (0.6–5.5)	2.1 (0.7–6.4)	32 (25–40)	5.8 (3.5–9.6)	6.9 (4.3–11.1)
Medication administered at home	98 (95–102)	8.4 (3.2–22.1)	10.0 (3.9–25.9)	93 (89–97)	16.9 (10.9–26.2)	20.1 (13.2–30.6)
Child care, preschool, or school day missed	48 (37–63)	4.1 (1.5–11.4)	4.9 (1.8–13.3)	37 (30–45)	6.6 (4.0–10.9)	7.9 (4.9–12.6)
Workday missed by caregiver	64 (53–77)	5.5 (2.0–14.7)	6.5 (2.5–17.2)	66 (59–74)	11.9 (7.6–18.8)	14.2 (9.2–21.9)

<sup>a</sup>One patient with influenza and 1 with RSV were lost to follow-up.

<sup>b</sup>Includes call to primary care clinic, visit to primary care clinic, additional visit to ED, or hospitalization not associated with enrollment encounter.

**TABLE 4**  
Antibiotic Use by Children Who Were 7 Years of Age and Treated in an ED for Influenza and RSV Infections

Type of Antibiotic Use	Influenza ( <i>n</i> = 58) <sup>a</sup>			RSV ( <i>n</i> = 150) <sup>a</sup>		
	Proportion (95% CI) Among Prospective Patients	Yearly Rate (95% CI) in Massachusetts Population/1000 Children	Yearly Rate (95% CI) in US Population/1000 Children	Proportion (95% CI) Among Prospective Patients	Yearly Rate (95% CI) in Massachusetts Population/1000 Children	Yearly Rate (95% CI) in US Population/1000 Children
Any antibiotic use	45 (34–60)	3.8 (1.4–10.7)	4.6 (1.7–12.4)	53 (46–62)	9.6 (6.0–15.3)	11.4 (7.3–17.8)
Antibiotic administered before ED visit	19 (11–32)	1.6 (0.5–5.1)	1.9 (0.6–5.8)	19 (14–27)	3.5 (2.0–6.2)	4.1 (2.4–7.1)
Antibiotic administered in ED	24 (15–37)	2.0 (0.7–6.2)	2.4 (0.8–7.1)	23 (17–31)	4.2 (2.4–7.2)	5.0 (3.0–8.3)
Antibiotic administered in hospital <sup>b</sup>	38 (15–92)	0.4 (0.1–2.3)	0.5 (0.1–2.5)	45 (34–60)	3.2 (1.8–5.8)	3.8 (2.4–6.1)
Antibiotic prescribed upon discharge from ED or hospital	12 (6–24)	1.0 (0.3–3.6)	1.2 (0.4–4.1)	14 (9–21)	2.5 (1.3–4.7)	3.0 (1.7–5.4)

<sup>a</sup>One patient with influenza and 1 with RSV were lost to follow-up.

<sup>b</sup>*n* = 8 for influenza and 59 for RSV.